Chinese tea chain Chagee revealed its revenue nearly tripled in 2024 as it filed for a US initial public offering (IPO) on ...
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
VESPER-2 is a 28-week Phase 2b clinical trial assessing the efficacy and tolerability of different weekly doses of MET-097i with or without titration. The trial enrolled the first participant in March ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback